KR101169846B1 - 시클릭 펩티드 ｃｘｃｒ４ 길항제 - Google Patents

시클릭 펩티드 ｃｘｃｒ４ 길항제 Download PDF

Info

Publication number
KR101169846B1
KR101169846B1 KR1020097024829A KR20097024829A KR101169846B1 KR 101169846 B1 KR101169846 B1 KR 101169846B1 KR 1020097024829 A KR1020097024829 A KR 1020097024829A KR 20097024829 A KR20097024829 A KR 20097024829A KR 101169846 B1 KR101169846 B1 KR 101169846B1
Authority
KR
South Korea
Prior art keywords
xaa
arg
res
mod
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097024829A
Other languages
English (en)
Korean (ko)
Other versions
KR20100003737A (ko
Inventor
웨인 데이비드 콘
쉥-빈 펭
리앙 젱 얀
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101169846(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20100003737A publication Critical patent/KR20100003737A/ko
Application granted granted Critical
Publication of KR101169846B1 publication Critical patent/KR101169846B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020097024829A 2007-05-30 2008-05-20 시클릭 펩티드 ｃｘｃｒ４ 길항제 Expired - Fee Related KR101169846B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94080207P 2007-05-30 2007-05-30
US60/940,802 2007-05-30
US94099607P 2007-05-31 2007-05-31
US60/940,996 2007-05-31
PCT/US2008/064177 WO2008150689A1 (en) 2007-05-30 2008-05-20 Cyclic peptide cxcr4 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020117026680A Division KR101319740B1 (ko) 2007-05-30 2008-05-20 시클릭 펩티드 ｃｘｃｒ４ 길항제

Publications (2)

Publication Number Publication Date
KR20100003737A KR20100003737A (ko) 2010-01-11
KR101169846B1 true KR101169846B1 (ko) 2012-08-01

Family

ID=39831600

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097024829A Expired - Fee Related KR101169846B1 (ko) 2007-05-30 2008-05-20 시클릭 펩티드 ｃｘｃｒ４ 길항제
KR1020117026680A Expired - Fee Related KR101319740B1 (ko) 2007-05-30 2008-05-20 시클릭 펩티드 ｃｘｃｒ４ 길항제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020117026680A Expired - Fee Related KR101319740B1 (ko) 2007-05-30 2008-05-20 시클릭 펩티드 ｃｘｃｒ４ 길항제

Country Status (32)

Country Link
US (3) US7691813B2 (enExample)
EP (2) EP2160221B1 (enExample)
JP (1) JP5358564B2 (enExample)
KR (2) KR101169846B1 (enExample)
CN (1) CN101678213B (enExample)
AR (1) AR066648A1 (enExample)
AT (1) ATE516853T1 (enExample)
AU (1) AU2008260326B2 (enExample)
BR (1) BRPI0812134A2 (enExample)
CA (1) CA2688574C (enExample)
CL (1) CL2008001467A1 (enExample)
CO (1) CO6241137A2 (enExample)
CR (1) CR11105A (enExample)
CY (1) CY1111815T1 (enExample)
DK (1) DK2160221T3 (enExample)
DO (1) DOP2009000270A (enExample)
EA (1) EA017716B1 (enExample)
GT (1) GT200900304A (enExample)
HR (1) HRP20110551T1 (enExample)
IL (1) IL201685A (enExample)
JO (1) JO2776B1 (enExample)
MA (1) MA31666B1 (enExample)
MX (1) MX2009012952A (enExample)
MY (1) MY149432A (enExample)
NZ (1) NZ580849A (enExample)
PE (1) PE20090299A1 (enExample)
PL (1) PL2160221T3 (enExample)
PT (1) PT2160221E (enExample)
TN (1) TN2009000496A1 (enExample)
TW (1) TWI423987B (enExample)
WO (1) WO2008150689A1 (enExample)
ZA (1) ZA200908345B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2942798B1 (fr) 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
IT1397901B1 (it) 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
WO2012118124A1 (ja) * 2011-03-01 2012-09-07 国立大学法人京都大学 新規ケモカイン受容体拮抗剤
ES2552944T3 (es) * 2011-06-07 2015-12-03 Polyphor Ag Peptidomiméticos de horquilla beta como antagonistas de CXCR4
WO2013044500A1 (zh) * 2011-09-30 2013-04-04 Cheng Yun 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用
US20140329809A1 (en) 2011-10-28 2014-11-06 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
EP2979991A1 (en) 2014-07-31 2016-02-03 Greif International Holding BV. Multilayer material, fire protection mat with said multilayer material and transport and storage container assembly comprising said fire protection mat.
EP3613435A1 (en) 2015-01-28 2020-02-26 Universite De Bordeaux Chemokine receptor cxcr4 inhibitors for treating and/or preventing chronic obstructive pulmonary disease
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
CN109922818B (zh) * 2016-09-06 2024-02-20 主线生物科学公司 Cxcr4拮抗剂及使用方法
CN106841624B (zh) * 2017-01-26 2019-02-22 庄磊靓 抗人cd4和抗人cd184单克隆抗体作为标志物的应用
US11123437B2 (en) * 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
EP3679053A4 (en) * 2017-09-05 2021-10-27 Mainline Biosciences CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USE
US11771736B2 (en) * 2017-12-21 2023-10-03 Mainline Biosciences (Shanghai) Co., Ltd. Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
CA3108450A1 (en) 2018-09-12 2020-03-19 Technische Universitat Munchen Cxcr4-targeted diagnostic and therapeutic agents with reduced species selectivity
EA202190755A1 (ru) 2018-09-12 2021-06-11 Технише Универзитет Мюнхен Агенты для терапии и диагностики рака
CN114364690A (zh) * 2019-04-18 2022-04-15 省卫生服务机构 用于诊断和治疗的新型放射性标记的cxcr4靶向化合物
EP4097120A4 (en) * 2020-01-26 2024-05-01 Mainline Biosciences (Shanghai) Co., Ltd. ISOTOPE-LABELED CXCR4 SELECTIVELY BINDING PEPTIDE CONJUGATE AND METHODS OF MAKING AND USE THEREOF
KR20230092906A (ko) * 2020-10-21 2023-06-26 프로빈셜 헬스 서비시즈 오쏘리티 신규한 cxcr4 표적화 화합물
CN116615411A (zh) * 2020-12-25 2023-08-18 中外制药株式会社 包含n-取代氨基酸残基的肽化合物的制造方法
JPWO2022138891A1 (enExample) * 2020-12-25 2022-06-30
EP4043041A1 (en) 2021-02-15 2022-08-17 Technische Universität München Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof
AU2023257191A1 (en) * 2022-04-20 2024-10-10 Alpha-9 Oncology Inc. Cxcr4-targeting compounds, and methods of making and using the same
CN115060901A (zh) * 2022-06-21 2022-09-16 中国医学科学院基础医学研究所 苹果酸酶2在制备矽肺病或肺纤维化相关疾病诊断试剂或治疗药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4391123B2 (ja) * 2002-10-24 2009-12-24 株式会社オーファンリンク 新規ｃｘｃｒ４アンタゴニスト
WO2007096662A2 (en) 2006-02-27 2007-08-30 Technische Universität München Cancer imaging and treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J Biomed Biotechnol. 2007; 2007: 26065.

Also Published As

Publication number Publication date
CY1111815T1 (el) 2015-10-07
CN101678213B (zh) 2013-11-06
CA2688574C (en) 2014-02-18
NZ580849A (en) 2012-03-30
EA200971129A1 (ru) 2010-04-30
CN101678213A (zh) 2010-03-24
CO6241137A2 (es) 2011-01-20
US20080300177A1 (en) 2008-12-04
ATE516853T1 (de) 2011-08-15
MX2009012952A (es) 2009-12-11
IL201685A0 (en) 2010-05-31
PE20090299A1 (es) 2009-03-19
US7691813B2 (en) 2010-04-06
PL2160221T3 (pl) 2011-12-30
WO2008150689A1 (en) 2008-12-11
EP2160221A1 (en) 2010-03-10
AR066648A1 (es) 2009-09-02
PT2160221E (pt) 2011-09-12
US20100130409A1 (en) 2010-05-27
KR20100003737A (ko) 2010-01-11
MA31666B1 (fr) 2010-09-01
JO2776B1 (en) 2014-03-15
EP2160221B1 (en) 2011-07-20
JP5358564B2 (ja) 2013-12-04
TWI423987B (zh) 2014-01-21
TN2009000496A1 (en) 2011-03-31
HK1141474A1 (en) 2010-11-12
KR101319740B1 (ko) 2013-10-17
HRP20110551T1 (hr) 2011-09-30
IL201685A (en) 2015-04-30
KR20110134519A (ko) 2011-12-14
ZA200908345B (en) 2011-02-23
CA2688574A1 (en) 2008-12-11
JP2010529957A (ja) 2010-09-02
CR11105A (es) 2010-04-12
BRPI0812134A2 (pt) 2014-11-18
AU2008260326B2 (en) 2011-07-21
DOP2009000270A (es) 2010-01-15
TW200902556A (en) 2009-01-16
CL2008001467A1 (es) 2008-12-05
DK2160221T3 (da) 2011-09-19
EP2377579A1 (en) 2011-10-19
USRE42274E1 (en) 2011-04-05
GT200900304A (es) 2011-11-09
AU2008260326A1 (en) 2008-12-11
MY149432A (en) 2013-08-30
EA017716B1 (ru) 2013-02-28

Similar Documents

Publication Publication Date Title
KR101169846B1 (ko) 시클릭 펩티드 ｃｘｃｒ４ 길항제
US20220257784A1 (en) Bicyclic peptide ligands specific for epha2
TW201305197A (zh) 葡萄糖依賴性促胰島素肽類似物
CN111183146A (zh) 高亲和力选择性结合cxcr4的缀合物及其使用方法
JP2009108078A (ja) ニューロメジンｂおよびソマトスタチンレセプターアゴニスト
CN113474046A (zh) Il-17特异性的双环肽配体
WO2015022283A1 (en) Yap-tead inhibitors
US10639379B2 (en) High affinity CXCR4 selective binding conjugate and method for using the same
JP2025508820A (ja) Ｃｒｆ２受容体アゴニスト及び治療法におけるそれらの使用
ES2367941T3 (es) Antagonistas cíclicos peptídicos de cxcr4.
CA2405724C (en) Substance p analogs for the treatment of cancer
HK1141474B (en) Cyclic peptide cxcr4 antagonists
WO2021123767A1 (en) Bicyclic peptide ligands specific for il-17
RS51950B (sr) Ciklični peptidi antagonisti cxcr4
KR101294895B1 (ko) 노시셉틴/오파닌 에프큐 수용체의 고강력 완전 및 부분작동물질 및 길항물질

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20150630

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160725

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160725